Consistently, a recent study showed that intravenous administration of human recombinant APOJ reduced insoluble Aβ levels and CAA in the brain of APP23 mice [102], raising the possibility of elevating plasma APOJ levels to mitigate Aβ pathology in AD. This evidence concerns the gene CLU and Alzheimer disease.